EuroPCR 2025

21 May 2025

STEMI Other coronary interventions

Redefining complex PCI: impact of real-world data and novel evidence on IV antithrombotic strategies

Sponsored by Chiesi Farmaceutici

Spokesperson: D. Angiolillo

Discussants: R. Mehran, J. Rymer, G. Friedrich, D. Cao

SHOW MORE

Summary

Explore how real-world data and evolving evidence are reshaping IV antithrombotic strategies in complex PCI. This EuroPCR 2025 session brings together urgent clinical cases—including STEMI patients in shock—and highlights key insights from the SMILE registry. Learn how transition protocols from cangrelor to oral P2Y12 inhibitors are applied in practice, compare approaches across Europe and the US, and get a forward-looking perspective on what’s next for IV therapies in 2025. A must-watch for anyone managing high-risk PCI.

Learning Objectives

To evaluate real-world evidence on antithrombotic strategies in clinical practice across Europe and USA
To analyse outcomes associated with the transition from cangrelor to oral P2Y12 inhibitors
To discuss implications of the findings on real-world evidence on state-of-the-art IV therapies in 2025

Jolanta Sille-rMatula

Speaker

J. Siller-Matula

Welcome and session objectives

Download presentation

Speaker

Clinical case: urgent PCI on STEMI patient

Download presentation

Speaker

Clinical case: a STEMI case presenting with cardiogenic shock

Download presentation

Roxana Mehran

Speaker

Clinical case: timing and transition protocols to oral P2Y12s

Download presentation

Roxana Mehran

Speaker

SMILE registry

Download presentation

Speaker

Future insights: IV therapies in 2025

Download presentation